The Foundation for Sarcoidosis Research and American Thoracic Society Announce Dr. Mark Mallozzi as the New FSR/ATS Partner Grant Awardee
The FSR/ATS Partner Grant, a cornerstone of both organizations' commitment to fostering early-career investigators, provides $100,000 in funding—$50,000 per year over two years—to support groundbreaking research projects that have the potential to significantly impact the understanding and treatment of sarcoidosis. Since 2005, this partnership has funded over $1 million in sarcoidosis research, catalyzing further advancements in the field.
'Dr. Mallozzi's grant will provide the scientific community with valuable insight into the environmental causes of sarcoidosis,' said Mary McGowan, President and CEO of FSR. 'We are pleased to partner with the American Thoracic Society to support dedicated investigators like Dr. Mallozzi who are committed to increasing the understanding of this complex disease.'This year's awardee, Mark Mallozzi, MD, MPH from National Jewish Health was selected for his project titled 'Association of PM2.5 exposure with sarcoidosis outcomes at baseline and longitudinal follow-up'. This study will look at a possible link between air pollution and sarcoidosis.
'This grant will be essential in advancing my career as a physician-scientist focusing on sarcoidosis and environmental exposures,' said Mark Mallozzi MD. 'Through this project, I will advance my research skills and scientific writing and presenting, build a network of collaborators, and produce foundational data for future projects. This project is a meaningful step in my goal of securing a National Institutes of Health Research Career Development Award (K).'
'We are immensely grateful to our non-profit partners for their continued collaboration and for their support of the young researchers who are contributing to greatly-improved outcomes for patients across the spectrum of respiratory health,' said Kamran Atabai, MD, chair of the ATS Scientific Grant Review Committee.
For more information about the FSR research funding programs, visit https://www.stopsarcoidosis.org/fsr-grants.
About SarcoidosisSarcoidosis is a rare inflammatory disease characterized by granulomas—tiny clumps of inflammatory cells—that can form in one or more organs. 90% of patients living with sarcoidosis have lung involvement. Despite advances in research, sarcoidosis remains challenging to diagnose, with limited treatment options and no known cure. Approximately 175,000 people live with sarcoidosis in the United States.
About the Foundation for Sarcoidosis ResearchThe Foundation for Sarcoidosis Research (FSR) is the leading international organization dedicated to finding a cure for sarcoidosis and improving care for those living with the disease through research, education, and support. For more information about FSR and its community programs, visit: www.stopsarcoidosis.org.
About the ATS FoundationSince its inception, the ATS Foundation Research Program has awarded more than $24 million in early career researchers has leveraged well over $880 million in NIH funding and breakthroughs in respiratory medicine. You can learn more about our most recent awardees here.
Media Contact:Cathi Davis, Director of Communications and MarketingFoundation for Sarcoidosis Research312-341-0500cathi@stopsarcoidosis.org
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/46aa564f-1606-4532-bb78-57eb14158704
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
01-07-2025
- Yahoo
Foundation for Sarcoidosis Research Announces Launch of Enhanced Sarcoidosis Data Registry
CHICAGO, July 01, 2025 (GLOBE NEWSWIRE) -- The Foundation for Sarcoidosis Research (FSR), the leading international organization dedicated to finding a cure for sarcoidosis and improving care for those affected, is proud to announce the launch of a new and enhanced version of the FSR-SARC Registry, the Sarcoidosis Advanced Registry for Cures. The FSR-SARC Registry is an IRB-approved, longitudinal, patient-powered database designed to accelerate sarcoidosis research by collecting critical insights on diagnosis, organ manifestation, treatments, symptoms, and impacts on quality of life. With nearly 7,000 participants from 68 different countries to date, the Registry is a cornerstone of FSR's mission to advance understanding and treatment of this complex and often misunderstood disease. The upgraded FSR-SARC Registry introduces a new, user-friendly platform (in partnership with Across Healthcare) with expanded features to maximize the impact of patient participation. Participants can now more easily share their experiences, update their information, and contribute to a growing body of knowledge that supports both clinical research and improved patient outcomes. Key Features and Benefits of the New FSR-SARC Registry: Enhanced Data Collection: The registry now captures even more comprehensive information on patients impacted by sarcoidosis. In addition to questionnaires and surveys, participants receiving care in the U.S. can link the Registry directly to their provider's patient portal. Improved Security and Privacy: Hosted on Across Healthcare's HIPAA-compliant platform, the Registry ensures that all personal health information is encrypted, securely stored, and only shared in de-identified form with approved researchers. Empowering Patient Voices: By enabling patients and caregivers to self-report their experiences, the registry provides critical insights into the variability, progression, and burden of sarcoidosis, informing future research and care recommendations. Facilitating Research and Clinical Trials: The registry connects interested patients to IRB-approved research opportunities based on both their eligibility and proximity to trial sites, helping to stimulate hypothesis-driven research and support the development of new treatments. Commitment to Representation and Access: FSR remains dedicated to expanding the variety of Registry participants and ensuring representation of all sarcoidosis patients. 'FSR is committed to empowering patients and accelerating research through the FSR-SARC Registry. We are immensely grateful for the extraordinary commitment of the sarcoidosis community in giving of their time and insights to inform and drive sarcoidosis research,' said Mary McGowan, President and CEO of FSR. 'Now in its tenth year, the Registry has been one of our most powerful tools to elevate patient voices in the advancement of sarcoidosis research. The enhanced surveys and platform represent a significant step forward in our efforts to drive innovation elevate patient-centered drug development, and improve patient outcomes for all impacted by sarcoidosis.' Participation in the FSR-SARC Registry is voluntary, confidential, and open to all individuals living with sarcoidosis or their caregivers. By joining, participants help shape the future of sarcoidosis research and care. For more information about the FSR-SARC Registry and to sign up, please visit About Sarcoidosis Sarcoidosis is a rare inflammatory disease characterized by granulomas—tiny clumps of inflammatory cells—that can form in one or more organs. 90% of patients living with sarcoidosis have lung involvement. Despite advances in research, sarcoidosis remains challenging to diagnose, with limited treatment options and no known cure. Approximately 175,000 people live with sarcoidosis in the United States. About the Foundation for Sarcoidosis Research The Foundation for Sarcoidosis Research (FSR) is the leading international organization dedicated to finding a cure for sarcoidosis and improving care for those living with the disease through research, education, and support. For more information about FSR and its community programs, visit: Media Contact: Cathi Davis, Director of Communications and Marketing Foundation for Sarcoidosis Research cathi@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Medscape
12-06-2025
- Medscape
Women With ILD Fare Better After ICU Care
Women admitted to ICU for interstitial lung disease (ILD) had shorter hospital stays and a lower risk for death than men, based on a new analysis of more than 800,000 individuals. Although previous studies have shown gender-based disparities in disease progression and severity for ILD based on subtype, data on the effect of gender on ICU outcomes in these patients are limited, according to Matthew Viggiano, MD, an internal medicine resident at Temple University Hospital, Philadelphia, and colleagues. In a study presented at the American Thoracic Society (ATS) 2025 International Conference, the researchers analyzed data from the National Inpatient Sample (NIS), part of the Healthcare Cost and Utilization Project for the period from 2016 to 2018. They identified 810,295 adults aged 18 years or older hospitalized with ILD, of whom 42,080 received ICU care. Of these, 46.7% were women. Female patients were significantly younger than male patients (mean age, 66.9 vs 69.1 years), more likely to be African American (17.0% vs 10.9%), and less likely to be Caucasian (63.7% vs 69.2%; P < .001 for all). Mortality was significantly lower in women than in men (40.5% vs 48.1%) even after adjusting for confounders including age, race, and comorbidities, and this difference was the most striking finding, Viggiano said in an interview. 'It also surprised us that these women tended to have a shorter length of hospital stay, given many came from lower-income areas,' he said. ICU stays were defined using International Classification of Diseases (ICD) codes for central line placement and mechanical ventilation. Overall, hospital stays for female patients lasted 1.15 days less than hospital stays for male patients. Female patients also were significantly more likely than male patients to come from lower-income ZIP codes (38.3% vs 33.2%) and less likely to have a history of tobacco use disorder (35.0% vs 43.9%; P < .001 for both). The reasons for the disparities remain unclear, but new studies suggest that hormones may play a role in disease progression and severity, Viggiano told Medscape Medical News . 'For example, estrogen has been implicated in modulating immune responses and fibrotic processes in the lungs via downregulating profibrotic pathways,' he said. 'Additionally, women may have lower threshold to seek medical attention or follow-up, leading to earlier intervention and management of ILD,' he noted. Other comorbidities unrelated to ILD also may contribute to morbidity and hospital length of stay, he added. 'Overall, recognizing these disparities is a key step toward more personalized treatment strategies, and our hope is that this research will prompt further studies to fully understand and address the underlying causes,' said Viggiano. Not Time for Gender Neutral Treatments Although the results suggest that clinicians should be aware that gender could influence ILD prognosis, the data do not suggest a need to advocate for entirely separate protocols as yet, Viggiano said. 'Instead, we encourage clinicians to recognize that men may have unique risk factors and might require more aggressive monitoring or early interventions; further studies will help refine specific management strategies,' he said. 'We believe evaluating for mortality and hospital stay in different subtypes of ILD would be an immediate future direction for the project,' said Viggiano. The investigation of specific biological, immunologic, and social factors also must be an area of focus, he said. 'Understanding why women fare better could lead to targeted therapies, especially for men who are at higher risk of poor outcomes, and ultimately to more personalized approaches to ILD care,' he added. To that end, Viggiano and colleagues intend to conduct prospective studies to explore specific biological markers and social determinants in men and women with ILD. 'We'll also look at the influence of treatment interventions, medication use, and rehabilitation services on outcomes. Ultimately, we'd like to identify targeted strategies to reduce the mortality gap and enhance care for both genders,' he told Medscape Medical News . Data Reinforce Differences 'As more treatments for interstitial lung diseases emerge, it is important that we now start focusing on which populations get the greatest benefit for specific treatments,' said Anthony Faugno, MD, a pulmonologist at Tufts Medicine, Boston, in an interview. To that end, the authors of the current study used data from the NIS to ask important questions about how sex, demographics, and socioeconomic factors affect patient outcomes, said Faugno, who was not involved in the study. Were You Surprised by Any of the Findings? Why or Why Not? Biologically important differences in hormones between men and women are known to affect the way a given disease behaves; therefore, it is important to have representative samples of diverse sex and race in clinical trials to ensure the generalizability of therapy, Faugno told Medscape Medical News . The current study findings were not surprisingbut reinforce the value of a diverse population using a large, nationally representative sample, he said. The current study findings may not directly affect clinical practice, as the results were based on ICD codes that cover many different diagnoses, Faugno noted. However, as the authors suggest, 'I do think it informs additional research directions, such as doing a similar analysis in specific interstitial diseases,' he said. The current study addresses a global catch-all term of ILD, which may include many different pathologies that respond to different treatments, said Faugno. 'A future analysis that addressed the gender disparities in more specific diagnoses would add to our understanding and help patients better understand how they may respond to a specific therapy,' he said.
Yahoo
05-06-2025
- Yahoo
The Foundation for Sarcoidosis Research and American Thoracic Society Announce Dr. Mark Mallozzi as the New FSR/ATS Partner Grant Awardee
CHICAGO, June 05, 2025 (GLOBE NEWSWIRE) -- The Foundation for Sarcoidosis Research (FSR) and the American Thoracic Society (ATS) are pleased to announce that Mark Mallozzi, MD, MPH has been selected to receive the 2025 ATS/FSR Partner Grant, awarded to support innovative research in sarcoidosis and advance patient care. The FSR/ATS Partner Grant, a cornerstone of both organizations' commitment to fostering early-career investigators, provides $100,000 in funding—$50,000 per year over two years—to support groundbreaking research projects that have the potential to significantly impact the understanding and treatment of sarcoidosis. Since 2005, this partnership has funded over $1 million in sarcoidosis research, catalyzing further advancements in the field. 'Dr. Mallozzi's grant will provide the scientific community with valuable insight into the environmental causes of sarcoidosis,' said Mary McGowan, President and CEO of FSR. 'We are pleased to partner with the American Thoracic Society to support dedicated investigators like Dr. Mallozzi who are committed to increasing the understanding of this complex disease.'This year's awardee, Mark Mallozzi, MD, MPH from National Jewish Health was selected for his project titled 'Association of PM2.5 exposure with sarcoidosis outcomes at baseline and longitudinal follow-up'. This study will look at a possible link between air pollution and sarcoidosis. 'This grant will be essential in advancing my career as a physician-scientist focusing on sarcoidosis and environmental exposures,' said Mark Mallozzi MD. 'Through this project, I will advance my research skills and scientific writing and presenting, build a network of collaborators, and produce foundational data for future projects. This project is a meaningful step in my goal of securing a National Institutes of Health Research Career Development Award (K).' 'We are immensely grateful to our non-profit partners for their continued collaboration and for their support of the young researchers who are contributing to greatly-improved outcomes for patients across the spectrum of respiratory health,' said Kamran Atabai, MD, chair of the ATS Scientific Grant Review Committee. For more information about the FSR research funding programs, visit About SarcoidosisSarcoidosis is a rare inflammatory disease characterized by granulomas—tiny clumps of inflammatory cells—that can form in one or more organs. 90% of patients living with sarcoidosis have lung involvement. Despite advances in research, sarcoidosis remains challenging to diagnose, with limited treatment options and no known cure. Approximately 175,000 people live with sarcoidosis in the United States. About the Foundation for Sarcoidosis ResearchThe Foundation for Sarcoidosis Research (FSR) is the leading international organization dedicated to finding a cure for sarcoidosis and improving care for those living with the disease through research, education, and support. For more information about FSR and its community programs, visit: About the ATS FoundationSince its inception, the ATS Foundation Research Program has awarded more than $24 million in early career researchers has leveraged well over $880 million in NIH funding and breakthroughs in respiratory medicine. You can learn more about our most recent awardees here. Media Contact:Cathi Davis, Director of Communications and MarketingFoundation for Sarcoidosis Research312-341-0500cathi@ A photo accompanying this announcement is available at
